Early results from the Phase I/II NXTAGE trial show that NXT007 may achieve hemostatic normalization in patients with ...

Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today positive phase I/II data on NXT007 in people with haemophilia A, ...

The pharma group has presented phase 1/2 results with new candidate NXT007 at the International Society on Thrombosis and ...

Chugai Pharma presents positive data from NXTAGE phase I/II study of NXT007 in people with haemophilia A at ISTH 2025 Congress: Tokyo Tuesday, June 24, 2025, 13:00 Hrs [IST] Chuga ...

Swiss pharma giant Roche has announced positive Phase I/II data on NXT007 in people with hemophilia A, supporting its ...

Early data suggest Roche’s NXT007 may have the potential to provide haemostatic normalisation in people with haemophilia A. Positive phase I/II data presented at the 2025 International Society ...

Chugai announced successful proof-of-concept results for NXT007, its next-generation Factor VIII mimetic for hemophilia patients, and will initiate three phase 3 trials next year.

NXT007 brings together factor IXa and factor X, proteins required to activate the natural coagulation cascade.1,2,3 NXT007 is being studied in a robust clinical development programme exploring its ...